The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with ...

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM ...

Abbott's growth potential with GLP-1 tailwinds, robust FCF, and dividend growth. Read more on how ABT navigates tariffs while ...

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

Two years ago, Eli Lilly started working with Dexcom to integrate continuous glucose monitoring (CGM) into its insulin delivery devices, and it has now firmed up the alliance. Lilly has taken a ...

Over the last 7 days, the United States market has remained flat, yet it has risen by 5.7% over the past year with earnings forecasted to grow by 13% annually. In this environment, identifying ...

Some stocks are lagging the market for good reasons -- because their businesses look shaky and their prospects uncertain.

Satio and Nanowear today announced that they partnered to advance patient-friendly, home-based diagnostic and therapeutic ...